Navigation Links
Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
Date:8/3/2009

SEATTLE, Aug. 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that clinical data relating to long-term treatment with Stimuvax were presented at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer in San Francisco on August 1, 2009. The presentation by Dr. Glenwood Goss from the Ottawa Hospital Cancer Centre, Ottawa, Ontario, involved 16 patients who received treatment with Stimuvax for between 2 and 8.2 years as part of the Phase 2b trial in patients with stage IIIb/IV non-small cell lung cancer (NSCLC).

As of the time of data analysis in April 2009, 10 of the 16 studied patients were alive without evidence of disease progression, of whom eight continued to receive therapy with Stimuvax after 6.3 to 8.2 years. The remaining two living patients discontinued Stimuvax therapy after 2.4 and 5.8 years, respectively, and were without evidence of disease progression. Nine of the 10 living patients had stage IIIb NSCLC upon entry to the trial, while one had stage IV disease. Six of the 10 living patients had a complete response to their first-line chemotherapy or chemo-radiation, while four patients had stable disease. The remaining six of the 16 patients discontinued Stimuvax after 2.0 to 5.1 years of treatment as a result of disease progression and are deceased.

Prolonged treatment with Stimuvax was well-tolerated in this trial. The most common treatment-related adverse events were injection-site reactions, which tended to diminish after the first year of treatment. There was no evidence of autoimmune reactions with prolonged use.

The Phase 2b trial of Stimuvax in patients with stage IIIb/IV NSCLC was conducted by Oncothyreon, with patient enrollment concluding in 2003. Long-term follow-up of these patients was conducted by Merck KGaA of Darmstadt,
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
2. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
3. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Oncothyreon announces closing of $11.1 million registered direct financing
5. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
6. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
7. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Oncothyreon reports first quarter 2009 financial results
9. Oncothyreon regains compliance with NASDAQ listing requirements
10. Oncothyreon to present at Invest Northwest 2009
11. Oncothyreon reports full year and fourth quarter 2008 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... HUYA Bioscience International (HUYA) today announced the sponsorship ... of HTLV-1, held this week at the University of ... Society is to promote research on HTLV-1 and HTLV-1-associated ... and research related to these fields to advance science, ... proud to support this prestigious conference," said Mireille ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... and expertly narrows down the product choices to a manageable shortlist of bench ... the list to models that fit best with the customer’s industry and application. ...
(Date:8/26/2015)... ... 2015 , ... MediVet Biologics, a leader in Veterinary Regenerative ... open in Manhattan, Kansas in early October, 2015. The location of the lab ... development through collaboration with researchers from Kansas State University’s College of Veterinary Medicine. ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, ... the development and manufacture of highly valued cardiac markers used in early detection ... expertise with protein chemistry has led to the development and commercialization of important ...
Breaking Biology Technology:HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4METTLER TOLEDO Updates Online Scale Selection Tool 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... December - - PC-Insulin Preclinical Study Results ... Biotechnologies,Inc. (TSX:CJB) announced today that dosing is complete ... Phase II trial was a,randomized, double-blind, placebo-controlled, multiple ... three months of weekly injections of,PC-DAC(TM):Exendin-4 in patients ...
... NOVATO, Calif., Nov. 5 BioMarin,Pharmaceutical Inc. (Nasdaq: ... of BioMarin, will present a company,update at the Credit ... November 12, 2008 at 10:30 a.m. MST., Interested ... conference,call via the investor section of the BioMarin website, ...
... DIEGO, Nov. 5 Ambrx Inc. today announced ... clinical trial of ARX201,the company,s long-acting human growth ... at the International Congress of,Endocrinology meeting in Rio ... and Vice President of Academic Affairs at Stanford ...
Cached Biology Technology:ConjuChem Provides Development Update 2ConjuChem Provides Development Update 3BioMarin to Present at the Credit Suisse Healthcare Conference 2Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue 2
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/3/2015)... 3, 2015 Synaptics, Inc. (Nasdaq: SYNA ... announced that members of the executive management team will ... Global Technology Leadership Forum on Tuesday, August 11, 2015 ... held at the Sonnenalp Resort in Vail, ... include forward-looking information. An audio webcast of the event ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... Highlights from the Lymphoma Research Foundation (LRF) 2009 Mantle Cell ... the March 2010 issue of Leukemia & Lymphoma. Traditionally ... Lymphoma has agreed to make this report available to the ... of the 2009 MCL Consortium Workshop. "It is gratifying ...
... Resistant wheat plants stave off attacks by Hessian fly larvae ... absorb nutrients, according to a study by Purdue University and ... - similar to human intestines - were observed in three ... function. Those that were given nothing to eat showed no ...
... Allergies and Infectious Diseases (NIAID), part of the National ... totaling $15,254,919 to Tulane University for its ongoing efforts ... viral disease that threatens hundreds of thousands of people ... potential bioterrorism threat. The contract will include collaboration ...
Cached Biology News:Resistant wheat goes for the gut to protect against Hessian flies 2Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
ANTI S. ENTERID LPS...
... ELISA Development kit contains the basic components ... to measure natural and recombinant Feline IL-10 ... kit contains sufficient materials to run ELISAs ... the following conditions are met: The ...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant rat ... Each kit contains sufficient materials to ... provided that the following conditions are met: ...
Biology Products: